Literature DB >> 21562709

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.

Makiko Ono1, Hitoshi Tsuda, Chikako Shimizu, Sohei Yamamoto, Tatsuhiro Shibata, Harukaze Yamamoto, Taizo Hirata, Kan Yonemori, Masashi Ando, Kenji Tamura, Noriyuki Katsumata, Takayuki Kinoshita, Yuichi Takiguchi, Hideki Tanzawa, Yasuhiro Fujiwara.   

Abstract

The purpose of the present study was to identify histological surrogate predictive markers of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC). Among 474 patients who received NAC and subsequent surgical therapy for stage II-III invasive breast carcinoma between 1999 and 2007, 102 (22%) had TNBC, and 92 core needle biopsy (CNB) specimens obtained before NAC were available. As controls, CNB specimens from 42 tumors of the hormone receptor-negative and HER2-positive (HR-/HER2+) subtype and 46 tumors of the hormone receptor-positive and HER2-negative (HR+/HER2-) subtype were also included. Histopathological examination including tumor-infiltrating lymphocytes (TIL) and tumor cell apoptosis, and immunohistochemical studies for basal markers were performed, and the correlation of these data with pathological therapeutic effect was analyzed. The rates of pCR at the primary site were higher for TNBC (32%) and the HR-/HER2+ subtype (21%) than for the HR+/HER2- subtype (7%) (P = 0.006). Expression of basal markers and p53, histological grade 3, high TIL scores, and apoptosis were more frequent in TNBC and the HR-/HER2+ subtype than in the HR+/HER2- subtype (P = 0.002 for TIL and P < 0.001 for others). In TNBC, the pCR rates of tumors showing a high TIL score and of those showing a high apoptosis score were 37 and 47%, respectively, and significantly higher or tended to be higher than those of the tumors showing a low TIL score and of the tumors showing a low apoptosis score (16 and 27%, respectively, P = 0.05 and 0.10). In a total of 180 breast cancers, the pCR rates of the tumors showing a high TIL score (34%) and of those showing a high apoptosis score (35%) were significantly higher than those of the tumors showing a low TIL score (10%) and those of the tumors showing a low apoptosis score (19%) (P = 0.0001 and 0.04, respectively). Histological grade and basal marker expression were not correlated with pCR. Although the whole analysis was exploratory, the degree of TIL correlated with immune response appear to play a substantial role in the response to NAC in TNBC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21562709     DOI: 10.1007/s10549-011-1554-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  123 in total

1.  Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.

Authors:  Gulsun Erdag; Jochen T Schaefer; Mark E Smolkin; Donna H Deacon; Sofia M Shea; Lynn T Dengel; James W Patterson; Craig L Slingluff
Journal:  Cancer Res       Date:  2012-01-19       Impact factor: 12.701

2.  Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis.

Authors:  Muyou Tian; Yahua Zhong; Fuxiang Zhou; Conghua Xie; Yunfeng Zhou; Zhengkai Liao
Journal:  Oncol Lett       Date:  2015-03-26       Impact factor: 2.967

3.  Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer.

Authors:  Christer Larsson; Anna Ehinger; Sofia Winslow; Karin Leandersson; Marie Klintman; Ludvig Dahl; Johan Vallon-Christersson; Jari Häkkinen; Cecilia Hegardt; Jonas Manjer; Lao Saal; Lisa Rydén; Martin Malmberg; Åke Borg; Niklas Loman
Journal:  NPJ Breast Cancer       Date:  2020-07-06

4.  Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.

Authors:  Rico D Bense; Christos Sotiriou; Martine J Piccart-Gebhart; John B A G Haanen; Marcel A T M van Vugt; Elisabeth G E de Vries; Carolien P Schröder; Rudolf S N Fehrmann
Journal:  J Natl Cancer Inst       Date:  2016-10-13       Impact factor: 13.506

5.  Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer.

Authors:  Jason R Brown; Hallie Wimberly; Donald R Lannin; Christian Nixon; David L Rimm; Veerle Bossuyt
Journal:  Clin Cancer Res       Date:  2014-09-25       Impact factor: 12.531

6.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

7.  Clinical characteristics and prognostic analysis of triple-negative breast cancer patients.

Authors:  Na Yuan; Min Meng; Caigang Liu; Lu Feng; Lei Hou; Qian Ning; Guohong Xin; Li Pei; Shanzhi Gu; Xiao Li; Xinhan Zhao
Journal:  Mol Clin Oncol       Date:  2013-12-20

8.  High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype.

Authors:  Jennifer B Dennison; Maria Shahmoradgoli; Wenbin Liu; Zhenlin Ju; Funda Meric-Bernstam; Charles M Perou; Aysegul A Sahin; Alana Welm; Steffi Oesterreich; Matthew J Sikora; Robert E Brown; Gordon B Mills
Journal:  Clin Cancer Res       Date:  2016-05-12       Impact factor: 12.531

Review 9.  Towards tumor immunodiagnostics.

Authors:  Helen Kourea; Vassiliki Kotoula
Journal:  Ann Transl Med       Date:  2016-07

10.  Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.

Authors:  Rebecca L Vartuli; Hengbo Zhou; Lingdi Zhang; Rani K Powers; Jared Klarquist; Pratyaydipta Rudra; Melanie Y Vincent; Debashis Ghosh; James C Costello; Ross M Kedl; Jill E Slansky; Rui Zhao; Heide L Ford
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.